semaglutide cardiovascular outcomes 2025 news oral indication in High-Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial ACC 2025: Oral Semaglutide Reduces – semaglutide cardiovascular outcomes 2025 news

, .

BPC-157 activates the EGR-1 and NAB2 feedback regulatory loop, essentially flipping genetic switches that initiate self-sustaining repair programs

I was not sick and I was able to lose weight in just one month

The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events